Aggressive primary cutaneous T-cell lymphoma Advocacy Hub | UniteRare

At a Glance

Live from database

🔬

54Recruiting trials

🩺

128Specialists

Regulatory Watchboard

10 events

Apr 2026Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)

Assistance Publique - Hôpitaux de Paris

TrialNOT YET RECRUITING

Mar 2026Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Medical College of Wisconsin — PHASE1

TrialNOT YET RECRUITING

Jan 2026A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Kyowa Kirin, Inc. — PHASE1

TrialNOT YET RECRUITING

Jan 2026A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Assistance Publique - Hôpitaux de Paris — EARLY_PHASE1

TrialNOT YET RECRUITING

Nov 2025Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance

Assistance Publique - Hôpitaux de Paris — PHASE3

TrialNOT YET RECRUITING

Sep 2025A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

National Cancer Institute (NCI) — PHASE1

TrialRECRUITING

Sep 2025Long-term Assessment of Chlormethine Gel in Mycosis Fungoides

Fondazione Italiana Linfomi - ETS

TrialNOT YET RECRUITING

Aug 2025Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

H. Lee Moffitt Cancer Center and Research Institute — PHASE1

TrialRECRUITING

Aug 2025A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Boston Immune Technologies and Therapeutics — PHASE1

TrialNOT YET RECRUITING

Jun 2025Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

UNC Lineberger Comprehensive Cancer Center — NA

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Aggressive primary cutaneous T-cell lymphoma.
Check the disease page for updates →

Clinical Trial Landscape

54 active trials

1Phase 3

1Phase 4

16Phase 2

13Phase 1

4N/A

13Unknown

6PHASE1, PHASE2

54Total recruiting

Search clinical trials for Aggressive primary cutaneous T-cell lymphoma →

Recent News & Research

No recent news articles indexed yet for Aggressive primary cutaneous T-cell lymphoma.
Search PubMed for Aggressive primary cutaneous T-cell lymphoma →

Browse all Aggressive primary cutaneous T-cell lymphoma news →

Specialist Network

Top 6 by expertise

Youn H Kim, MD

Stanford University

Score 383 trials

Christiane Querfeld, MD, PhD

City of Hope Medical Center

📍 DUARTE, CA

Score 332 trials3 pubs

Pietro Quaglino, MD

SC Dermatologia U - A.O.U. Città della Salute e della Scienza di Torino

Score 332 trials

Youn H Kim

Stanford University

Score 322 trials771 pubs

Barbara Pro, MD, M.D

Columbia University

📍 NEW YORK, NY

Score 225 trials

Project Leader

Ono Pharmaceutical Co. Ltd

Score 2011 trials

View all Aggressive primary cutaneous T-cell lymphoma specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰